Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2015-01, Vol.2015 (2015), p.1-4
Main Authors: Santos-Oliveira, Ralph, Orlando, Margarida Maria Camoes, Perini, Jamila Alessandra, Machado, Daniel Escorsim
Format: Article
Language:English
Subjects:
Abdomen
Angiogenesis
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacokinetics
Animals
Bevacizumab - pharmacokinetics
Breast cancer
Cancer therapies
Diagnosis
Disease
Drug dosages
Endometriosis
Endometriosis - diagnostic imaging
Endometriosis - metabolism
Female
Gene expression
Genetic aspects
Isotope Labeling - methods
Labeling
Laboratories
Metabolic Clearance Rate
Metastasis
Nuclear medicine
Observations
Organ Specificity
Pathogenesis
Quality control
Radionuclide Imaging - methods
Radiopharmaceuticals - chemical synthesis
Radiopharmaceuticals - pharmacokinetics
Rats
Reproducibility of Results
Sensitivity and Specificity
Spleen
Technetium
Tissue Distribution
Transplants & implants
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab.
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/751460